Search Results - "Cadoo, Karen"

CLINICAL UTILITY OF PROSPECTIVE MOLECULAR CHARACTERIZATION IN ADVANCED ENDOMETRIAL CANCER by Soumerai, Tara E, Donoghue, Mark T A, Bandlamudi, Chaitanya, Srinivasan, Preethi, Chang, Matthew T, Zamarin, Dmitriy, Cadoo, Karen, Grisham, Rachel, O'Cearbhaill, Roisin E, Tew, William, Konner, Jason, Hensley, Martee L, Makker, Vicky, Sabbatini, Paul J, Spriggs, David R, Troso-Sandoval, Tiffany, Snyder Charen, Alexandra, Friedman, Claire F, Gorsky, Mila, Schweber, Sarah J, Middha, Sumit, Murali, Rajmohan, Chiang, Sarah, Park, Kay J, Soslow, Robert A, Ladanyi, Marc, Li, Bob T, Mueller, Jennifer J, Weigelt, Britta, Zehir, Ahmet, Berger, Michael F, Abu-Rustum, Nadeem R, Aghajanian, Carol, DeLair, Deborah, Solit, David B, Taylor, Barry S, Hyman, David M

“…Advanced-stage endometrial cancers have limited treatment options and poor prognosis, highlighting the need to understand genetic drivers of therapeutic…”
Get full text

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing by Mandelker, Diana, Zhang, Liying, Kemel, Yelena, Stadler, Zsofia K, Joseph, Vijai, Zehir, Ahmet, Pradhan, Nisha, Arnold, Angela, Walsh, Michael F, Li, Yirong, Balakrishnan, Anoop R, Syed, Aijazuddin, Prasad, Meera, Nafa, Khedoudja, Carlo, Maria I, Cadoo, Karen A, Sheehan, Meg, Fleischut, Megan H, Salo-Mullen, Erin, Trottier, Magan, Lipkin, Steven M, Lincoln, Anne, Mukherjee, Semanti, Ravichandran, Vignesh, Cambria, Roy, Galle, Jesse, Abida, Wassim, Arcila, Marcia E, Benayed, Ryma, Shah, Ronak, Yu, Kenneth, Bajorin, Dean F, Coleman, Jonathan A, Leach, Steven D, Lowery, Maeve A, Garcia-Aguilar, Julio, Kantoff, Philip W, Sawyers, Charles L, Dickler, Maura N, Saltz, Leonard, Motzer, Robert J, O’Reilly, Eileen M, Scher, Howard I, Baselga, José, Klimstra, David S, Solit, David B, Hyman, David M, Berger, Michael F, Ladanyi, Marc, Robson, Mark E, Offit, Kenneth

“…IMPORTANCE: Guidelines for cancer genetic testing based on family history may miss clinically actionable genetic changes with established implications for…”
Get full text

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial by Konstantinopoulos, Panagiotis A, Barry, William T, Birrer, Michael, Westin, Shannon N, Cadoo, Karen A, Shapiro, Geoffrey I, Mayer, Erica L, O'Cearbhaill, Roisin E, Coleman, Robert L, Kochupurakkal, Bose, Whalen, Christin, Curtis, Jennifer, Farooq, Sarah, Luo, Weixiu, Eismann, Julia, Buss, Mary K, Aghajanian, Carol, Mills, Gordon B, Palakurthi, Sangeetha, Kirschmeier, Paul, Liu, Joyce, Cantley, Lewis C, Kaufmann, Scott H, Swisher, Elizabeth M, D'Andrea, Alan D, Winer, Eric, Wulf, Gerburg M, Matulonis, Ursula A

“…Based on preclinical work, we found that combination of poly (ADP-ribose) polymerase (PARP) inhibitors with drugs that inhibit the homologous recombination…”
Get full text

Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers by Veeraraghavan, Harini, Friedman, Claire F., DeLair, Deborah F., Ninčević, Josip, Himoto, Yuki, Bruni, Silvio G., Cappello, Giovanni, Petkovska, Iva, Nougaret, Stephanie, Nikolovski, Ines, Zehir, Ahmet, Abu-Rustum, Nadeem R., Aghajanian, Carol, Zamarin, Dmitriy, Cadoo, Karen A., Diaz, Luis A., Leitao, Mario M., Makker, Vicky, Soslow, Robert A., Mueller, Jennifer J., Weigelt, Britta, Lakhman, Yulia

“…To evaluate whether radiomic features from contrast-enhanced computed tomography (CE-CT) can identify DNA mismatch repair deficient (MMR-D) and/or tumor…”
Get full text

First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors by Tao, Jessica J, Cangemi, Nicholas A, Makker, Vicky, Cadoo, Karen A, Liu, Joyce F, Rasco, Drew W, Navarro, Willis H, Haqq, Christopher M, Hyman, David M

“…STM 434 is a soluble receptor ligand trap targeting activin A, a protein in the TGFβ family that plays important roles in growth, differentiation, and cancer…”
Get full text

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study by Moore, Kathleen N, Chambers, Setsuko K, Hamilton, Erika P, Chen, Lee-May, Oza, Amit M, Ghamande, Sharad A, Konecny, Gottfried E, Plaxe, Steven C, Spitz, Daniel L, Geenen, Jill J J, Troso-Sandoval, Tiffany A, Cragun, Janiel M, Rodrigo Imedio, Esteban, Kumar, Sanjeev, Mugundu, Ganesh M, Lai, Zhongwu, Chmielecki, Juliann, Jones, Suzanne F, Spigel, David R, Cadoo, Karen A

“…This study assessed the efficacy, safety, and pharmacokinetics of adavosertib in combination with four chemotherapy agents commonly used in patients with…”
Get full text

The context-specific role of germline pathogenicity in tumorigenesis by Srinivasan, Preethi, Bandlamudi, Chaitanya, Jonsson, Philip, Kemel, Yelena, Chavan, Shweta S., Richards, Allison L., Penson, Alexander V., Bielski, Craig M., Fong, Christopher, Syed, Aijazuddin, Jayakumaran, Gowtham, Prasad, Meera, Hwee, Jason, Sumer, Selcuk Onur, de Bruijn, Ino, Li, Xiang, Gao, JianJiong, Schultz, Nikolaus, Cambria, Roy, Galle, Jesse, Mukherjee, Semanti, Vijai, Joseph, Cadoo, Karen A., Carlo, Maria I., Walsh, Michael F., Mandelker, Diana, Ceyhan-Birsoy, Ozge, Shia, Jinru, Zehir, Ahmet, Ladanyi, Marc, Hyman, David M., Zhang, Liying, Offit, Kenneth, Robson, Mark E., Solit, David B., Stadler, Zsofia K., Berger, Michael F., Taylor, Barry S.

“…Human cancers arise from environmental, heritable and somatic factors, but how these mechanisms interact in tumorigenesis is poorly understood. Studying 17,152…”
Get full text

Palbociclib: an evidence-based review of its potential in the treatment of breast cancer by Cadoo, Karen A, Gucalp, Ayca, Traina, Tiffany A

“…Cellular proliferation, growth, and division following DNA (deoxyribonucleic acid) damage are tightly controlled by the cell-cycle regulatory machinery. This…”
Get full text

Cancer Susceptibility Mutations in Patients With Urothelial Malignancies by Carlo, Maria I, Ravichandran, Vignesh, Srinavasan, Preethi, Bandlamudi, Chaitanya, Kemel, Yelena, Ceyhan-Birsoy, Ozge, Mukherjee, Semanti, Mandelker, Diana, Chaim, Joshua, Knezevic, Andrea, Rana, Satshil, Fnu, Zarina, Breen, Kelsey, Arnold, Angela G, Khurram, Aliya, Tkachuk, Kaitlyn, Cipolla, Catharine K, Regazzi, Ashley, Hakimi, A Ari, Al-Ahmadie, Hikmat, Dalbagni, Guido, Cadoo, Karen A, Walsh, Michael F, Teo, Min-Yuen, Funt, Samuel A, Coleman, Jonathan A, Bochner, Bernard H, Iyer, Gopa, Solit, David B, Stadler, Zsofia K, Zhang, Liying, Rosenberg, Jonathan E, Taylor, Barry S, Robson, Mark E, Berger, Michael F, Vijai, Joseph, Bajorin, Dean F, Offit, Kenneth

“…Urothelial cancers (UCs) have a substantial hereditary component, but, other than their association with Lynch syndrome, the contribution of genetic risk…”
Get full text

Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer by Stasenko, Marina, Tunnage, Irina, Ashley, Charles W., Rubinstein, Maria M., Latham, Alicia J., Da Cruz Paula, Arnaud, Mueller, Jennifer J., Leitao, Mario M., Friedman, Claire F., Makker, Vicky, Soslow, Robert A., DeLair, Deborah F., Hyman, David M., Zamarin, Dimitriy, Alektiar, Kaled M., Aghajanian, Carol A., Abu-Rustum, Nadeem R., Weigelt, Britta, Cadoo, Karen A.

“…Assess outcomes of a clinical cohort of patients with endometrioid endometrial cancer (EEC) harboring somatic POLE exonuclease domain mutations (EDMs)…”
Get full text

Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade by Boland, Julia L., Zhou, Qin, Martin, Madhuri, Callahan, Margaret K., Konner, Jason, O'Cearbhaill, Roisin E., Friedman, Claire F., Tew, William, Makker, Vicky, Grisham, Rachel N., Hensley, Martee L., Zecca, Nicholas, Iasonos, Alexia E., Snyder, Alexandra, Hyman, David M., Sabbatini, Paul, Aghajanian, Carol, Cadoo, Karen A., Zamarin, Dmitriy

“…Delayed responses observed with immune checkpoint blockade (ICB) present a challenge for patients with peritoneal malignancies, who risk early symptomatic…”
Get full text

Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy by Boland, Julia L., Zhou, Qin, Iasonos, Alexia E., O'Cearbhaill, Roisin E., Konner, Jason, Callahan, Margaret, Friedman, Claire, Aghajanian, Carol, Sabbatini, Paul, Zamarin, Dmitriy, Cadoo, Karen A.

“…This study aimed to evaluate the utility of serum cancer antigen-125 (CA-125) levels to monitor patients with epithelial ovarian cancer (EOC) undergoing immune…”
Get full text

Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers by Ehmann, Sarah, Sassine, Dib, Straubhar, Alli M, Praiss, Aaron M, Aghajanian, Carol, Alektiar, Kaled M, Broach, Vance, Cadoo, Karen A, Jewell, Elizabeth L, Boroujeni, Amir Momeni, Kyi, Chrisann, Leitao, Mario M, Mueller, Jennifer J, Murali, Rajmohan, Bhaloo, Shirin Issa, O'Cearbhaill, Roisin E, Park, Kay J, Sonoda, Yukio, Weigelt, Britta, Zamarin, Dmitriy, Abu-Rustum, Nadeem, Friedman, Claire F

“…Gastric-type endocervical adenocarcinoma (GEA) is a rare form of cervical cancer not associated with human papilloma virus (HPV) infection. We summarize our…”
Get full text

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer by Jhaveri, Komal, Wang, Rui, Teplinsky, Eleonora, Chandarlapaty, Sarat, Solit, David, Cadoo, Karen, Speyer, James, D'Andrea, Gabriella, Adams, Sylvia, Patil, Sujata, Haque, Sofia, O'Neill, Tara, Friedman, Kent, Esteva, Francisco J, Hudis, Clifford, Modi, Shanu

“…Targeted therapies in HER2-positive metastatic breast cancer significantly improve outcomes but efficacy is limited by therapeutic resistance. HER2 is an…”
Get full text

Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status by Stasenko, Marina, Cybulska, Paulina, Feit, Noah, Makker, Vicky, Konner, Jason, O'Cearbhaill, Roisin E., Alektiar, Kaled M., Beal, Kathryn, Gardner, Ginger J., Long Roche, Kara C., Sonoda, Yukio, Chi, Dennis S., Zivanovic, Oliver, Leitao, Mario M., Cadoo, Karen A., Tew, William P.

“…To evaluate clinical outcomes of patients with BRCA-associated ovarian cancer who developed brain metastases (BM). Patients with epithelial ovarian, fallopian…”
Get full text

Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma by Carlo, Maria I, Mukherjee, Semanti, Mandelker, Diana, Vijai, Joseph, Kemel, Yelena, Zhang, Liying, Knezevic, Andrea, Patil, Sujata, Ceyhan-Birsoy, Ozge, Huang, Kuo-Cheng, Redzematovic, Almedina, Coskey, Devyn T, Stewart, Carolyn, Pradhan, Nisha, Arnold, Angela G, Hakimi, A Ari, Chen, Ying-Bei, Coleman, Jonathan A, Hyman, David M, Ladanyi, Marc, Cadoo, Karen A, Walsh, Michael F, Stadler, Zsofia K, Lee, Chung-Han, Feldman, Darren R, Voss, Martin H, Robson, Mark, Motzer, Robert J, Offit, Kenneth

“…Identification of patients with hereditary renal cell carcinoma (RCC) is important for cancer screening and, in patients with advanced disease, for guiding…”
Get more information

Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer by Mukherjee, Semanti, Bandlamudi, Chaitanya, Hellmann, Matthew D, Kemel, Yelena, Drill, Esther, Rizvi, Hira, Tkachuk, Kaitlyn, Khurram, Aliya, Walsh, Michael F, Zauderer, Marjorie G, Mandelker, Diana, Topka, Sabine, Zehir, Ahmet, Srinivasan, Preethi, Esai Selvan, Myvizhi, Carlo, Maria I, Cadoo, Karen A, Latham, Alicia, Hamilton, Jada G, Liu, Ying L, Lipkin, Steven M, Belhadj, Sami, Bond, Gareth L, Gümüş, Zeynep H, Klein, Robert J, Ladanyi, Marc, Solit, David B, Robson, Mark E, Jones, David R, Kris, Mark G, Vijai, Joseph, Stadler, Zsofia K, Amos, Christopher I, Taylor, Barry S, Berger, Michael F, Rudin, Charles M, Offit, Kenneth

“…The genetic factors that modulate risk for developing lung cancer have not been fully defined. Here, we sought to determine the prevalence and clinical…”
Get full text

Pathogenic germline variants in patients with endometrial cancer of diverse ancestry by Liu, Ying L., Gordhandas, Sushmita, Arora, Kanika, Rios‐Doria, Eric, Cadoo, Karen A., Catchings, Amanda, Maio, Anna, Kemel, Yelena, Sheehan, Margaret, Salo‐Mullen, Erin, Zhou, Qin, Iasonos, Alexia, Carrot‐Zhang, Jian, Manning‐Geist, Beryl, Sia, Tiffany Y., Selenica, Pier, Vanderbilt, Chad, Misyura, Maksym, Latham, Alicia, Bandlamudi, Chaitanya, Berger, Michael F., Hamilton, Jada G., Makker, Vicky, Abu‐Rustum, Nadeem R., Ellenson, Lora H., Offit, Kenneth, Mandelker, Diana L., Stadler, Zsofia, Weigelt, Britta, Aghajanian, Carol, Brown, Carol

“…Background Racial disparities in outcomes exist in endometrial cancer (EC). The contribution of ancestry‐based variations in germline pathogenic variants…”
Get full text

Comprehensive analysis of germline drivers in endometrial cancer by Gordhandas, Sushmita, Rios-Doria, Eric, Cadoo, Karen A, Catchings, Amanda, Maio, Anna, Kemel, Yelena, Sheehan, Margaret, Ranganathan, Megha, Green, Dina, Aryamvally, Anjali, Arnold, Angela G, Salo-Mullen, Erin, Manning-Geist, Beryl, Sia, Tiffany, Selenica, Pier, Da Cruz Paula, Arnaud, Vanderbilt, Chad, Misyura, Maksym, Leitao, Mario M, Mueller, Jennifer J, Makker, Vicky, Rubinstein, Maria, Friedman, Claire F, Zhou, Qin, Iasonos, Alexia, Latham, Alicia, Carlo, Maria I, Murciano-Goroff, Yonina R, Will, Marie, Walsh, Michael F, Issa Bhaloo, Shirin, Ellenson, Lora H, Ceyhan-Birsoy, Ozge, Berger, Michael F, Robson, Mark E, Abu-Rustum, Nadeem, Aghajanian, Carol, Offit, Kenneth, Stadler, Zsofia, Weigelt, Britta, Mandelker, Diana L, Liu, Ying L

“…Abstract Background We sought to determine the prevalence of germline pathogenic variants (gPVs) in unselected patients with endometrial cancer (EC), define…”
Get full text

Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations by Liu, Ying L, Cadoo, Karen A, Mukherjee, Semanti, Khurram, Aliya, Tkachuk, Kaitlyn, Kemel, Yelena, Maio, Anna, Belhadj, Sami, Carlo, Maria I, Latham, Alicia, Walsh, Michael F, Dubard-Gault, Marianne E, Wang, Yuhan, Brannon, A Rose, Salo-Mullen, Erin, Sheehan, Margaret, Fiala, Elise, Devolder, Bryan, Dandiker, Sita, Mandelker, Diana, Zehir, Ahmet, Ladanyi, Marc, Berger, Michael F, Solit, David B, Bandlamudi, Chaitanya, Ravichandran, Vignesh, Bajorin, Dean F, Stadler, Zsofia K, Robson, Mark E, Vijai, Joseph, Seshan, Venkatraman, Offit, Kenneth

“…Cancer survivors are developing more subsequent tumors. We sought to characterize patients with multiple (≥2) primary cancers (MPC) to assess associations and…”
Get full text